October 21, 2021
Amsterdam, the Netherlands and Chicago, USA Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new innovations that will help improve cancer care across the patient journey at the American Society for Radiation Oncology (ASTRO) annual meeting (Chicago, USA, 24-27 October). During the event, Philips will debut its Multimodality RT Simulation Workspace, a new precision medicine application that provides a vendor-agnostic single space for simulation, multimodality image fusion and contouring. New MR and CT imaging systems tailored for the needs of radiation therapy will also be showcased, delivering breakthroughs in imaging and treatment planning. Philips will also highlight its deepened strategic partnership with Elekta to support the ambition of providing clear care pathways and predictable outcomes for every cancer patient.
Today, cancer care is a long, complex journey through various stages, settings, and providers, putting a significant burden on both patients and clinicians. The number of new cancer cases is expected to rise by about 70% over the next two decades [1]. At the same time, oncology care is transforming, driven by an increasingly precise diagnosis of each tumor, and a continuously expanding range of therapy options. To fully capitalize on these challenges and opportunities, healthcare providers require integrated solutions throughout the entire cancer care pathway, from diagnosis to treatment and follow-up.
Enhanced through strategic partnerships, our end-to-end oncology solutions span the patient pathway and the multidisciplinary specialties, integrating data and enabling collaboration, all with the aim of improving patient and staff satisfaction and outcomes, said Ardie Ermers, General Manager Oncology Solutions at Philips. At this years ASTRO meeting were highlighting how were connecting clinical and operational teams with the information they need to optimize and personalize cancer care.
Bringing clarity in therapy planning closer to the point of care with Multimodality RT Simulation WorkspaceWith images and data often siloed in different systems, the complexity of image fusion and contouring can lengthen patient time to treatment. Integrating seamlessly into the simulation workflow, Multimodality RT Simulation Workspace, a new precision medicine application, is designed to help physicians define tumor volume and surrounding organs-at-risk through a versatile multimodality image platform which connects to both Philips and non-Philips imaging devices or a Picture Archiving and Communication System (PACS) to access image datasets such as CT, MR, PET, Spectral CT and Cone Beam CT. These capabilities provide better access to a task-centered, vendor neutral solution that efficiently utilizes all available images and data in one central location.
Innovations in MR and CT simulation deliver advances in imaging and treatment planningWith the companys strong track record of bringing continuous innovations to expand the role of MRI in radiation therapy, the next-generation Philips MR Ingenia RT XD MR simulation platform has been designed around the needs of radiation oncology, combining ease-of-use, streamlined integration and versatility. The platform can be easily adapted for different procedures, including external beam radiation therapy (EBRT), proton therapy and brachytherapy planning. The new Couch Top RT XD with Unity indexing further extends the compatibility between the Philips MR Ingenia RT XD and Elekta Unity, supporting greater consistency in both image quality and imaging and positioning workflows that enhance reproducibility, help accelerate learning curves and drive continuity across the care path.
The recently-introduced Spectral CT 7500 system delivers high quality spectral images for every patient on every scan 100% of the time to help improve disease characterization, and reduce rescans and follow-ups, all at the same dose levels as conventional scans. Unlocking the clinical value of dual-energy CT for radiation oncology applications, Spectral CT allows for optimization of lesions that may represent cancer. By capturing additional information such as electron density and effective atomic number, Spectral CT enables physicians to quantify physiological processes such as perfusion and ventilation, enhancing treatment planning.
Philips is collaborating with MIM Software to integrate its Contour ProtgAI next-generation deep learning segmentation on its CT Big Bore RT platform, providing automatically segmented Organ at Risk segmentation immediately after the simulation exam [2].
Further expansion of precision medicine application portfolioAlso being introduced at ASTRO, Multidisciplinary Team Orchestrator virtually connects and securely integrates multi-disciplinary teams and data across the patient cancer journey. Together with Multimodality RT Simulation Workspace, applications already available from Philips that advance precision oncology through integrated care, pathway orchestration, and clinical decision support, include:
Partnering to benefit patients throughout the care pathwayIn June, Philips and Elekta announced that the two healthcare leaders would deepen their strategic partnership in precise and individualized oncology care. The strengthened strategic partnership intends to further deliver an excellent experience in diagnosis and adaptive, personalized treatments for clinicians, shorter treatment times and precise therapy for patients, and lowered costs of care for healthcare providers. As part of the partnership, Philips will develop seamless integration between its precision medicine applications and Elektas MOSAIQ Plaza integrated radiotherapy software suite, enhancing end-to-end decision making and treatment implementation.
For more information about Philips presence at ASTRO 2021 follow @PhilipsLiveFrom for updates throughout the event.
[1] WHO International Agency for Research on Cancer https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf%5B2%5D Big Bore RT with Contour ProtgAI is only available in the USAMultimodality RT Simulation Workspace is a new feature of the TumorLoc module, part of Pinnacle RTPS. Both TumorLoc and Pinnacle are FDA cleared
For further information, please contact:
Kathy OReillyPhilips Global Press OfficeTel.: +1 978 221 8919E-mail: kathy.oreilly@philips.com
Mark GrovesPhilips Global Press OfficeTel.: +31 631 639 916Email: mark.groves@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.com/newscenter.
Read the original post:
Philips brings clarity to every moment of cancer care with new patient-centered innovations at ASTRO 2021 - GlobeNewswire
- Personalized medicine could transform healthcare - PMC - April 24th, 2025
- Genomic medicine and personalized treatment: a narrative review - April 24th, 2025
- Podcast: Ochre Bios Approach To Precision Medicine In Liver Treatment - insights.citeline.com - April 24th, 2025
- Reinforcement Learning in Personalized Medicine: A Comprehensive Review of Treatment Optimization Strategies - Cureus - April 24th, 2025
- Evolving Biomarkers: Charting the Future of Precision Medicine - MarketScale - April 24th, 2025
- Next Generation Tissue Biomarkers Market Size Report 2030 - Grand View Research - April 24th, 2025
- City of Hope Research on Artificial Intelligence (AI), Precision Medicine, Immunotherapies and Other Topics to be Presented at American Association of... - April 24th, 2025
- What the Newest mRNA Vaccines Could Do Beyond COVID - News-Medical - April 24th, 2025
- Opinion: Where public health ends and personalised medicine begins - Pulse+IT News - April 24th, 2025
- Crohns Disease Treatment Market to Reach $5.9 Billion by 2034, Driven by Biologics & Precision Medicine - Global Banking | Finance | Review - April 24th, 2025
- The Role of High Throughput Screening in Precision Medicine and Market Growth In New Report - WhaTech - April 24th, 2025
- Antiviral Chewing Gum May Prevent Flu and Herpes Transmission - Inside Precision Medicine - April 14th, 2025
- Wisconsin's role in the next advances in health care - BizTimes - April 14th, 2025
- The Future of Pulmonary Fibrosis Management: Precision Medicine, Biomarkers and AI - Managed Healthcare Executive - April 14th, 2025
- Leading Driver In The Jetrea Market 2025: Rise Of Personalized Medicine Fueling Growth - EIN News - March 9th, 2025
- Personalized Medicine Market Overview 2024-2025 & 2030: Oncology, Neurology, and Cardiology Lead Expansion, ext-Generation Sequencing and AI... - March 9th, 2025
- Innovations in core-shell nanoparticles advance drug delivery and precision medicine - Phys.org - March 9th, 2025
- Personalized Medicine: Motivation, Challenges and Progress - February 24th, 2025
- Healthcare innovations in predictive analytics, AI, and personalized medicine - HealthLeaders Media - February 24th, 2025
- Healthcare innovations in predictive analytics, AI, and personalized medicine - Fast Company - February 24th, 2025
- Artificial Intelligence (Ai) In Precision Medicine Market to See Robust Growth from USD 2.14 Billion to USD - EIN News - February 24th, 2025
- BMY: 3 Precision Medicine Stocks That Could Transform Healthcare - StockNews.com - February 24th, 2025
- Cracking Cancers Code: How Genetic Testing Is Changing the Treatment Game - geneonline - February 24th, 2025
- Curt Medeiros on Revolutionizing Precision Medicine and Scaling Ovation - Madrona Venture Group - January 6th, 2025
- Personalized medicine: The pros, cons and concerns - New Atlas - November 16th, 2024
- Precision Medicine, AI, and the Future of Personalized Health Care - November 16th, 2024
- Why precision medicine results in more effective health care, treatment plans - The Business Journals - November 16th, 2024
- Comprehensive Genomic Profiling at Diagnosis Extends Survival in Patients with Advanced Cancer - Inside Precision Medicine - November 16th, 2024
- More Precise Classifications of NonClear Cell RCC Are Required to Improve Personalized Treatment - OncLive - September 13th, 2024
- Bahrain aims to provide residents with personalized healthcare - Healthcare IT News - September 13th, 2024
- Precision Medicine Market Is Expected To Reach Revenue Of - GlobeNewswire - September 13th, 2024
- New Graduates Leverage Genomics Education in Clinical and Research Settings - University of Colorado Anschutz Medical Campus - June 20th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022